Breast Cancer — Expanded Access Programs

• Study Comparing 5-Day vs. 9-Day Whole Breast Radiation with Boost for Early-Stage Breast Cancer — University of Utah
• Study on ST101 for Patients with Advanced Solid Tumors — Sapience Therapeutics
• Study on the Safety and Effectiveness of ENV-501 for Patients with HER3-Positive Solid Tumors — Endeavor Biomedicines, Inc.
• Study on TER-2013 for Patients with Advanced Solid Tumors with Specific Genetic Changes — Terremoto Biosciences Inc.
• Phase 2 Study of Zanidatamab and Chemotherapy for HER2-positive Breast Cancer Before Surgery — Jazz Pharmaceuticals
• Phase 2 Study of Zanidatamab for Early Stage HER2 Positive Breast Cancer — M.D. Anderson Cancer Center
• Phase 2 Study of Zanidatamab for Patients with HER2-positive Tumors — Jazz Pharmaceuticals
• Study on [177Lu]Lu-NeoB and Capecitabine for Treating Advanced Breast Cancer — Novartis Pharmaceuticals
• Study on AZD8205 Alone or with Other Cancer Drugs for Advanced or Metastatic Solid Tumors — AstraZeneca
• Phase II Study on Inavolisib, Ribociclib, and Fulvestrant for Advanced Breast Cancer — Hoffmann-La Roche
• Phase 3 Study Comparing Dato-DXd to Standard Chemotherapy in Patients with Advanced HR-Positive, HER2-Negative Breast Cancer — AstraZeneca
• Study on Inavolisib, Palbociclib, and Fulvestrant for Advanced Breast Cancer with PIK3CA Mutation — Hoffmann-La Roche
• Study on Inavolisib with CDK4/6 Inhibitor and Letrozole vs Placebo for Advanced Breast Cancer with Specific Mutations — Hoffmann-La Roche
• Study on Dato-DXd for Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer — AstraZeneca
• Study Comparing Dato-DXd with Chemotherapy for Patients with Advanced Triple-negative Breast Cancer Not Suitable for PD-1/PD-L1 Inhibitors — AstraZeneca
• Study on Disitamab Vedotin for Adults with Advanced HER2 Positive Breast Cancer — Pfizer
• Study Comparing Elacestrant to Standard Hormone Therapy in Women and Men with Early Breast Cancer at High Risk of Returning — Stemline Therapeutics, Inc.
• Study on Emiltatug Ledadotin (Emi-Le) for Patients with Solid Tumors — Day One Biopharmaceuticals, Inc.
• Study on MT-4561 for Patients with Advanced Solid Tumors — Mitsubishi Tanabe Pharma America Inc.
• Study on Nonsteroidal Aromatase Inhibitors and Abemaciclib for Postmenopausal Women with Breast Cancer — Eli Lilly and Company
• Study on PARG Inhibitor ETX-19477 for Patients with Advanced Solid Cancers — 858 Therapeutics, Inc.
• Study on T-DXd for Patients with Advanced HER2 Positive Breast Cancer, With or Without Brain Metastasis — AstraZeneca
• Study on How Hormone Therapy Before Surgery Affects Breast Cancer Treatment Outcomes — Memorial Sloan Kettering Cancer Center
• Study on GDC-4198 Alone and with Giredestrant Compared to Abemaciclib and Giredestrant for Advanced ER+ HER2- Breast Cancer — Genentech, Inc.
• Study on PF-07248144 and Fulvestrant for HR-positive, HER2-negative Advanced or Metastatic Breast Cancer After Previous Treatment — Pfizer
• Study on Inavolisib Treatments for Early-Stage, PIK3CA-Mutated Breast Cancer — Hoffmann-La Roche
• Study on AMXI-5001 for Treating Advanced Cancers — AtlasMedx, Incorporated
• Study on Abraxane® With or Without Mifepristone for Advanced Triple-Negative Breast Cancer — University of Chicago
• Accelerated Radiation Therapy for Breast Cancer and Nearby Lymph Nodes — Weill Medical College of Cornell University
• Study on Aggressive Local Therapy for Bone-Only Metastasis to Improve Outcomes in Breast Cancer Patients — M.D. Anderson Cancer Center
• Study on Atezolizumab and Sacituzumab Govitecan to Prevent Recurrence in Triple Negative Breast Cancer (ASPRIA) — Dana-Farber Cancer Institute
• ATOP Trial: Investigating T-DM1 for HER2 Positive Breast Cancer — Dana-Farber Cancer Institute
• Study on Axelopran for Advanced Cancer in Patients Using Opioids — HealthPartners Institute
• Study on Entrectinib for Treating Solid Tumors with Specific Gene Changes — Hoffmann-La Roche
• Study on Preoperative Pembrolizumab and Radiation for Breast Cancer — Stephen Shiao
• Study on Carboplatin with or without Nivolumab for Treating Metastatic Triple Negative Breast Cancer — Dana-Farber Cancer Institute
• Study on Carboplatin and Nab-Paclitaxel With or Without Vorinostat for Treating Women with Newly Diagnosed Operable Breast Cancer — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Study on Cisplatin, Romidepsin, and Nivolumab for Locally Recurrent or Metastatic Triple Negative Breast Cancer — Priyanka Sharma
• Study on Combination Chemotherapy With or Without Trastuzumab for Stage II or III Breast Cancer — City of Hope Medical Center
• Study Comparing Two Doses of Fulvestrant in Postmenopausal Women with Advanced Breast Cancer — AstraZeneca
• Study on Using Deslorelin with Low-Dose Estradiol and Testosterone to Prevent Breast Cancer in Premenopausal Women at High Risk — City of Hope Medical Center
• Study Comparing DS-8201a and T-DM1 for HER2-Positive Breast Cancer That Cannot Be Removed or Has Spread — Daiichi Sankyo
• Study on the Effectiveness and Safety of 500mg Fulvestrant for Breast Cancer — Beth Israel Deaconess Medical Center
• EMERALD: Study on Using Only Radiation Therapy After Surgery in ER+ Breast Cancer for Women Aged 60 and Older — M.D. Anderson Cancer Center
• Study on Endocrine Therapy With or Without Abemaciclib After Surgery for Breast Cancer — Eli Lilly and Company
• Study on New Biomarker-Driven Treatments for Advanced Breast Cancer — UNC Lineberger Comprehensive Cancer Center
• Study on Using Enzalutamide for Early Stage Androgen Receptor Positive Triple Negative Breast Cancer — Memorial Sloan Kettering Cancer Center
• Study on HER2 FPBMC Treatment for Patients with Metastatic Breast and Prostate Cancer — University of Virginia
• HERizon-Breast: Personalized Treatment Study for Long-Term Remission in HER2+ Metastatic Breast Cancer — Memorial Sloan Kettering Cancer Center
• Study on Higher or Standard Daily Radiation Therapy for Early-Stage Breast Cancer After Surgery — Radiation Therapy Oncology Group
• Study on Letrozole with Ribociclib or Placebo as Pre-Surgery Treatment for ER-positive, HER2-negative Early Breast Cancer — Qamar Khan
• Study on Using Genetically Modified T Cells to Treat Malignant Pleural Disease — Memorial Sloan Kettering Cancer Center
• Access Programs for Alpelisib (BYL719) — Novartis Pharmaceuticals
• Study on Margetuximab or Trastuzumab for Stage II-III HER2-Positive Breast Cancer — Dana-Farber Cancer Institute
• Study on Predicting Endocrine Resistance in Hormone Receptor-Positive HER2-Negative Breast Cancer — Medical College of Wisconsin
• Study on Using Carboplatin and Docetaxel Before Surgery for Triple Negative Breast Cancer — Mothaffar Rimawi
• Study on Neoadjuvant Endocrine Therapy, Palbociclib, and Avelumab for Estrogen Receptor Positive Breast Cancer — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Study on Neoadjuvant HER2-Targeted Therapy and Immunotherapy with Pembrolizumab for HER2-Positive Breast Cancer — University of Texas Southwestern Medical Center
• Study on Nivolumab and Ipilimumab for Treating Metastatic Hypermutated HER2-negative Breast Cancer — Dana-Farber Cancer Institute
• Study on Nivolumab, Ipilimumab, and Bicalutamide for HER2 Negative Breast Cancer Patients — Providence Health & Services
• Study on Olaparib as Additional Treatment for Patients with High-Risk HER2 Negative Breast Cancer with BRCA Mutations — AstraZeneca
• Study on Paclitaxel Albumin-Stabilized Nanoparticle Formulation for Treating Metastatic Breast Cancer in Patients of Different Ages — City of Hope Medical Center
• Study on Palazestrant and Ribociclib for First-time Treatment of ER+/HER2- Advanced Breast Cancer — Olema Pharmaceuticals, Inc.
• Study on Palbociclib and Hormone Therapy Before Surgery for Lobular Breast Cancer — Dana-Farber Cancer Institute
• Study on Adding Palbociclib to Standard Hormone Therapy for Early HR+/HER2- Breast Cancer — Alliance Foundation Trials, LLC.
• Study on Pembrolizumab, IRX-2, and Chemotherapy for Triple Negative Breast Cancer — Providence Health & Services
• Study on Pertuzumab and Trastuzumab as Pre-Surgery Treatment for HER2-Positive Breast Cancer — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Study on PF-07104091 as a Single Treatment and in Combination for Advanced Cancers — Pfizer
• Study on Finding the Right Dose and Safety of a New Treatment for Advanced Solid Tumors — MBrace Therapeutics
• Phase 3 Study of Gedatolisib as First-Line Treatment for HR-Positive, HER2-Negative Advanced Breast Cancer — Celcuity Inc
• Phase 3 Study Comparing RLY-2608 + Fulvestrant and Capivasertib + Fulvestrant for Advanced PIK3CA-mutant HR+/HER2- Breast Cancer — Relay Therapeutics, Inc.
• Phase II Study of Pembrolizumab and Nab-paclitaxel for HER-2 Negative Metastatic Breast Cancer — NYU Langone Health
• Phase II Study Comparing Capecitabine and Elacestrant with Capecitabine Alone in ER+ Breast Cancer (CAPELA) — Kristina A. Fanucci
• Phase II Study on Personalized Radiation and Sentinel Lymph Node Biopsy for Early-stage ER+ Breast Cancer — University of Texas Southwestern Medical Center
• Study on Preoperative Chemotherapy, Pembrolizumab, and Radiation for Node-Positive, Triple Negative Breast Cancer — UNC Lineberger Comprehensive Cancer Center
• Study on Preoperative Fulvestrant With or Without Enzalutamide for ER+/Her2- Breast Cancer — University of Colorado, Denver
• Study on Single-Dose Radiation Therapy Before Surgery for Early Stage Breast Cancer — Duke University
• Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer — Memorial Sloan Kettering Cancer Center
• Study on Proton Radiation for Stage II/III Breast Cancer — Proton Collaborative Group
• Study on Radiation Therapy for Women with Early Stage Breast Cancer — Rutgers, The State University of New Jersey
• Continuation Study for Patients Who Benefited from a Previous Cancer Study with Olaparib — AstraZeneca
• Study on Chemotherapy Combinations for Treating Breast Cancer After Surgery — SWOG Cancer Research Network
• Study on Sacituzumab Govitecan and Zimberelimab with Radiation for Treating Metastatic Triple Negative Breast Cancer with Brain Metastases — H. Lee Moffitt Cancer Center and Research Institute
• Safety Extension Study for Patients with HR+, HER2- Breast Cancer Who Completed the OVELIA Study — Tolmar Inc.
• Study on Shorter Radiation Schedules for Breast Cancer Patients After Surgery — M.D. Anderson Cancer Center
• Study on LEE011, BYL719, and Letrozole for Advanced ER+ Breast Cancer — Novartis Pharmaceuticals
• Study on Olaparib and Durvalumab for HER2 Negative BRCA-Mutated Breast Cancer — AstraZeneca
• Study on Patritumab Deruxtecan and Pembrolizumab with Other Cancer Drugs for High-Risk Early-Stage Breast Cancer — Merck Sharp & Dohme LLC
• Study of Patritumab Deruxtecan with Other Cancer Drugs for HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed — Merck Sharp & Dohme LLC
• Study of Pembrolizumab with Chemotherapy and Hormone Therapy for Early-Stage ER+/HER2- Breast Cancer — Merck Sharp & Dohme LLC
• Study of Pembrolizumab and Fulvestrant for Advanced Hormone Receptor Positive, HER-2 Negative Breast Cancer — Nancy Chan, MD
• Study of PF-07220060 and Letrozole for Adults with HR-positive HER2-negative Advanced Breast Cancer — Pfizer
• Study on Zelenectide Pevedotin for Advanced Breast Cancer — BicycleTx Limited
• Study on T-DM1 and Pertuzumab Before Surgery for Early-Stage HER2-Positive Breast Cancer — Dana-Farber Cancer Institute
• Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer — Stanford University
• The AVIATOR Study: Testing Drug Combinations for Advanced HER2+ Breast Cancer — Adrienne G. Waks
• The SAPPHO Study: Testing a New Treatment Plan for HER2+ Metastatic Breast Cancer — Dana-Farber Cancer Institute
• Study on the Effects of Inavolisib and Fulvestrant for Breast Cancer Patients — Hoffmann-La Roche
• Study on Trastuzumab Deruxtecan (T-DXd) Alone or with THP Compared to Standard Treatment for HER2-positive Early Breast Cancer — AstraZeneca
• Study on Treating ADC-Refractory Breast Cancer with Dato-DXd or T-DXd: TRADE DXd — Ana C Garrido-Castro, MD
• Study on Anastrozole and Palbociclib for Treating Metastatic HER2-Negative Breast Cancer — Wake Forest University Health Sciences
• Study Comparing Two Pre-Surgery Treatments for HER2-Positive Breast Cancer — University of Kansas Medical Center
• Trial of Pre-operative Neratinib and Hormone Therapy with Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers — Ruth O'Regan
• Study on Dendritic Cell Vaccine with Trastuzumab or Nivolumab for Breast Cancer with Leptomeningeal Disease — H. Lee Moffitt Cancer Center and Research Institute
• Comparing One-Week and Two-Week Radiation Therapy for Early Breast Cancer — Weill Medical College of Cornell University
• Study on Ultra Hypo-fractionated Radiation Therapy with Boost for Early-Stage Breast Cancer — UNC Lineberger Comprehensive Cancer Center
• Study on KVA12123 Treatment Alone and with Pembrolizumab for Advanced Solid Tumors (VISTA-101) — Kineta Inc.
• Study on the Safety and Effectiveness of AB-201 for Advanced HER2+ Solid Tumors — Artiva Biotherapeutics, Inc.
• Study on [225Ac]-FPI-1434 Injection for Patients with Advanced Solid Tumors — Fusion Pharmaceuticals Inc.
• A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors — Valerio Therapeutics
• Study on ARV-471 Alone and with Palbociclib for Advanced ER+/HER2- Breast Cancer — Arvinas Estrogen Receptor, Inc.
• Phase 2 Study of PCS6422 with Capecitabine for Advanced or Metastatic Breast Cancer — Processa Pharmaceuticals
• Study on New Combination of Low Dose Cyclophosphamide with Axatilimab and Retifanlimab for Treating Metastatic Triple Negative Breast Cancer — M.D. Anderson Cancer Center
• Phase II Study of Sacituzumab Govitecan and Pembrolizumab Before Surgery for Early-stage Triple-negative Breast Cancer Resistant to Immunochemotherapy — M.D. Anderson Cancer Center
• Phase III Study on Dato-DXd and Durvalumab for Pre- and Post-Surgery Treatment of Certain Types of Breast Cancer — AstraZeneca
• Phase III Study of Dato-DXd With or Without Durvalumab vs. Chemotherapy and Pembrolizumab for PD-L1 Positive Advanced Triple-negative Breast Cancer — AstraZeneca
• Phase II Study of Hormone Therapy, Pertuzumab, and Trastuzumab for Stage I Hormone Receptor-Positive, HER2-Positive Breast Cancer — Dana-Farber Cancer Institute
• A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy — Hoffmann-La Roche
• Study Comparing Inavolisib Plus Fulvestrant with Alpelisib Plus Fulvestrant for Advanced Breast Cancer with Specific Mutations — Hoffmann-La Roche
• Study on BB-1701 for Patients with HER2-Positive or HER2-Low Advanced Breast Cancer — Eisai Inc.

Looking for a program not shown above? Search the full catalog for “Breast Cancer” to see every match including additional filters.